Comparative Pharmacology
Head-to-head clinical analysis: DIETHYLPROPION HYDROCHLORIDE versus MAZANOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIETHYLPROPION HYDROCHLORIDE versus MAZANOR.
DIETHYLPROPION HYDROCHLORIDE vs MAZANOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sympathomimetic amine with anorectic activity; stimulates release of norepinephrine and dopamine from presynaptic nerve terminals in the hypothalamus, leading to appetite suppression.
Mazanor (mazindol) is a sympathomimetic amine that acts as an anorectic agent. It likely reduces appetite by increasing norepinephrine and dopamine levels in the hypothalamic feeding centers via reuptake inhibition and possibly by blocking serotonin receptors.
25 mg orally three times daily, 1 hour before meals; extended-release: 75 mg orally once daily in midmorning.
1 mg orally once daily, titrated based on response and tolerability up to 2 mg once daily.
None Documented
None Documented
4-6 hours (parent drug); clinical effects correlate with plasma levels, requiring multiple daily dosing.
Terminal half-life is 12-15 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours).
Approximately 70-80% of the dose is excreted renally as metabolites; less than 10% as unchanged drug. Biliary/fecal excretion accounts for the remainder.
Primarily renal (85-90% as unchanged drug), with minor biliary/fecal elimination (5-10%).
Category C
Category C
Appetite Suppressant
Appetite Suppressant